dronedarone

基本解釋

This article will review evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation.
這篇文章將回顧決奈達隆在房顫患者中應用的安全性和有效性。
Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of atrial fibrillation and atrial flutter.
決奈達隆是胺碘酮的一種非碘化苯并呋喃衍生物逐漸發(fā)展為房顫和房撲的治療藥物。
Dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure.
決奈達隆減少高危房顫患者的死亡率和發(fā)病率，但在嚴重心衰患者中應用可能不安全。
Prior analyses have established that dronedarone is effective both in controlling ventricular rate and in maintaining normal sinus rhythm.
此前的分析已經(jīng)證實，決奈達隆在控制心室率和維持正常的竇性節(jié)律方面兼具療效。
Dronedarone is manufactured by Sanofi-Aventis.A new drug application was filed in June 2005 and is currently under review by the US Food and Drug Administration.
他附帶表示，未來需要這2個藥物互相比較的臨床試驗，但是這將需要非常大的試驗樣本。